Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 13/20 | 0.40 |
| ▸ | SCD | O00767 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17920287 | 0.88 | ROCK2 (0.47) | ROCK2SCDGPR119USP30TP53 | |
| SCHEMBL17913000 | 0.83 | ROCK2 (0.46) | ROCK2 | |
| SCHEMBL17913005 | 0.76 | ACE (0.40) | USP30 | |
| SCHEMBL19759532 | 0.75 | BRD4 (0.59) | ROCK2BRD4 | |
| SCHEMBL25445548 | 0.74 | ROCK2 (0.56) | ROCK2SCDGPR119USP30 | |
| SCHEMBL19759533 | 0.72 | BRD4 (0.51) | BRD4 | |
| SCHEMBL13144317 | 0.69 | ROCK2 (0.57) | ROCK2SCDGPR119USP30 | |
| SCHEMBL17920292 | 0.68 | ROCK2 (0.53) | ROCK2BRD4 | |
| SCHEMBL15742917 | 0.67 | ROCK2 (0.60) | ROCK2SCDGPR119USP30 | |
| SCHEMBL3087005 | 0.67 | ROCK2 (0.60) | ROCK2SCDGPR119USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180000788-A1 | CYCLIC UREAS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000788-A1 | CYCLIC UREAS AS INHIBITORS OF ROCK | MYLK, ROCK1, UACA | ROCK2 4/4885BRD4 2814/4885SCD 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.